Biotechnology

Amarin

Amarin released FY2026 Q1 earnings on April 29 Pre-Market (EST), actual revenue USD 45.13 M (forecast USD 43.77 M), actual EPS USD -0.6 (forecast USD 0.01)

Amarin to Release FY2026 Q1 Earnings on April 29 Pre-Market EST, Forecast Revenue USD 43.77 M, EPS USD 0.01

Amarin released FY2025 earnings on February 25 Pre-Market (EST), actual revenue USD 213.65 M (forecast USD 215.08 M), actual EPS USD -1.8698 (forecast USD -0.095)

Amarin released FY2025 Q4 earnings on February 25 Pre-Market (EST), actual revenue USD 49.22 M (forecast USD 50.62 M), actual EPS USD -0.0588 (forecast USD -0.01)

Amarin to release FY2025 Q4 earnings on February 25 Pre-Market EST, forecast revenue USD 50.62 M, EPS USD -0.01

Amarin Publishes New Analysis Proving VASCEPA/VAZKEPA Reduces Cardiovascular Risk

Amarin released FY2025 Q3 earnings on October 29 Pre-Market EST, actual revenue USD 49.67 M (forecast USD 43.1 M), actual EPS USD -0.4 (forecast USD -0.4298)

Amarin released FY2025 9 Months Earnings on October 29 Pre-Market EST, with actual revenue of USD 164.43 M and actual EPS of USD -1.8822

Amarin Supports FDA Revision to Non-Statins Fibrate Drug Label

Amarin to Release FY2025 Q3 Earnings on October 29 Pre-Market EST, Forecast Revenue USD 34.65M, EPS USD -0.4298

Amarin Reveals Anti-Inflammatory Mechanism of EPA

Amarin released FY2025 Semi-Annual earnings on July 30 Pre-Market (EST), actual revenue USD 114.76 M, actual EPS USD -1.4413

Amarin released FY2025 Q2 earnings on July 30 Pre-Market (EST), actual revenue USD 72.74 M (forecast USD 53.76 M), actual EPS USD -0.6822 (forecast USD -0.2493)

Amarin to Release FY2025 Q2 Earnings on July 30 Pre-Market (EST), Forecast Revenue USD 53.76M, EPS USD -0.2493

Goldman Sachs Maintains Amarin Corp Rating and Adjusts Target Price

Amarin Corporation Signs VAZKEPA Commercialization Agreement with Recordati

Amarin released FY2025 Q1 earnings on May 7 Pre-Market EST, actual revenue USD 42.02 M (forecast USD 50.75 M), actual EPS USD -0.8 (forecast USD -0.77)

Amarin Corp to Release Quarterly Earnings Report

Amarin Reports Q1 2025 Earnings with 57c EPS Loss

Amarin to Release FY2025 Q1 Earnings on May 7 Pre-Market EST, Forecast Revenue USD 50.75 M, EPS USD -0.77

Freecast

Cuprina

U-BX Tech

HORIZON SPACE ACQUISITION II CORP COM USD0.0001 30/03/2026(SUB/RIGHTS)

Defiance Pure Space Dly 2X Strat ETF

VS MEDIA

Everbright Digital

Park Ha Biological Tech

Friedman Industries

Defiance Daily Target 2X Short ASTS ETF

Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma | HIK Stock News

StockTitan

Hikma Pharmaceuticals Plc

Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma | HIK Stock News

AMRN

Healthcare stocks rose late Thursday, with the NYSE Healthcare Index up 3.2%. Eli Lilly gained 4.3% on a $1.9B licensing deal; Merck climbed 5% after settling Gardasil lawsuits for over $50M. Amarin fell 4.4% due to a Supreme Court patent ruling. UnitedHealth surged 5.4% following a BofA upgrade to 'buy' citing improved medical cost trends and favorable Q2 data.

Fidelity

Eli Lilly

Unitedhealth

Merck

Health Care Select Sector SPDR

iShares Biotechnology ETF

Sector Update: Healthcare Stocks Climb Late Afternoon

The US Supreme Court ruled against Amarin (AMRN) in a patent dispute regarding its drug Vascepa. The Court determined that Amarin failed to prove generic manufacturer Hikma Pharmaceuticals actively induced infringement of two patents after Hikka received approval for a 'skinny-label' generic version. Consequently, Amarin's complaint was dismissed. Amarin expressed disappointment and stated it is evaluating next steps while remaining committed to its mission.

Update: Supreme Court Rules Against Amarin in 'Skinny Label' Patent Case

Amarin Corporation plc presented new data from the REDUCE-IT trial at the EAS Congress 2026, suggesting risk-weighted apolipoprotein B (RW-apoB) as a method for identifying cardiovascular disease. The trial, which involved 8,179 patients, showed that icosapent ethyl reduced LDL-C levels and cardiovascular risk. RW-apoB levels were found to be 30% higher in CVD patients compared to measured apoB levels. The company also recommended high doses of icosapent ethyl for very high-risk CVD patients. AMRN shares closed at $14.52, up 1.54%.

nasdaq

Nasdaq

Amarin Presents RW-ApoB As Risk Identifier For Cardiovascular Disease Based On REDUCE-IT Data

At Amarin's AGM on May 13, 2026, shareholders rejected proposals to expand the board's authority for issuing new shares and increasing the Stock Incentive Plan, while re-electing key directors. This decision limits the board's ability to grant equity incentives, increasing reliance on cash compensation. Analysts rate AMRN stock as a Sell with a $12.00 price target, citing persistent unprofitability despite a strong balance sheet and improved cash-flow trends.

Tip Ranks

Amarin Shareholders Reject Dilution, Governance Proposals at AGM

Amarin(AMRN.US)

Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma | HIK Stock News

Sector Update: Healthcare Stocks Climb Late Afternoon

Update: Supreme Court Rules Against Amarin in 'Skinny Label' Patent Case

Amarin Presents RW-ApoB As Risk Identifier For Cardiovascular Disease Based On REDUCE-IT Data

Amarin Shareholders Reject Dilution, Governance Proposals at AGM